Revolution Medicines, Inc. (FRA:42Z)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.63B +320.6% |
| Revenue (ttm) | n/a |
| Net Income | -1.19B |
| EPS | -6.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 131.65 |
| Previous Close | 134.05 |
| Day's Range | 131.65 - 135.15 |
| 52-Week Range | 29.60 - 160.65 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
News
Revolution Medicines price target raised to $182 from $165 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $182 from $165 and keeps an Outperform rating on the shares. The company’s daraxonrasib will be able to…
Wedbush reiterates Outperform on Revolution Medicines after ASCO data
Wedbush analyst Robert Driscoll notes that Revolution Medicines (RVMD) presented full RASolute-302 data at ASCO 2026 Plenary Session, with results published simultaneously in the NEJM, confirming the ...
Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $195 from $169 and keeps a Buy rating on the shares after the company presented the full results…
Revolution Medicines price target raised to $195 from $165 at Oppenheimer
Oppenheimer raised the firm’s price target on Revolution Medicines (RVMD) to $195 from $165 and keeps an Outperform rating on the shares. At ASCO 2026, additional RASolute-302 data strengthened daraxo...
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
Revolution Medicines Transcript: Status update
Daraxonrasib demonstrated unprecedented survival and response benefits in metastatic pancreatic cancer, doubling median overall survival and showing a strong safety profile. Regulatory filings and expanded access are underway, with a robust pipeline and global launch preparations advancing.
Revolution Medicines Slides: Status update
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on May 31, 2026.
Revolution Medicines announces results from Phase 3 RASolute 302 trial
Revolution Medicines (RVMD) announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients w...
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
Revolution's pancreatic cancer drug doubles survival, boosts quality of life
Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume activities they had previously aband...
Bernstein starts Revolution Medicines at Market Perform, says upside baked in
Bernstein initiated coverage of Revolution Medicines (RVMD) with a Market Perform rating and $151 price target The firm believes investors should pass on RevMed at this time because the value…
Revolution Medicines initiated with a Market Perform at Bernstein
Bernstein analyst Jeffrey Walch initiated coverage of Revolution Medicines (RVMD) with a Market Perform rating and $151 price target
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ca...
Revolution Medicines assumed with a Buy at Truist
Truist assumed coverage of Revolution Medicines (RVMD) with a Buy rating and price target of $179, up from $116. The firm views daraxon as the “leading anchor” across RAS-mutant cancers.
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a spee...
Revolution Medicines price target raised to $185 from $170 at BofA
BofA analyst Alex Stranahan raised the firm’s price target on Revolution Medicines (RVMD) to $185 from $170 and keeps a Buy rating on the shares. The Q1 report “largely reinforced…
Revolution Medicines price target raised to $172 from $120 at Piper Sandler
Piper Sandler analyst Kelsey Goodwin raised the firm’s price target on Revolution Medicines (RVMD) to $172 from $120 and keeps an Overweight rating on the shares. The firm notes the…
Revolution Medicines price target raised to $205 from $175 at Guggenheim
Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $205 from $175 and keeps a Buy rating on the shares after the company reported Q1 results and highlighted…
Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
Cash, cash equivalents and marketable securities were $1.9B as of March 31. In April, the company received $2.1B in net proceeds from concurrent financings. “Last month we reported positive results…
Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
Revolution Medicines (RVMD) updated its FY26 GAAP operating expenses guidance to a range of $1.7B-$1.8B. The expected increase in operating expenses is due to higher projected non-cash stock-based com...
Revolution Medicines announces NEJM publication of data on Daraxonrasib
The company states: “Revolution Medicines (RVMD) announced that The New England Journal of Medicine, NEJM, has published a report describing data from the Phase 1/2 clinical trial evaluating daraxonra...
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scien...
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side effects...
Revolution Medicines Earnings Call Transcript: Q1 2026
Daraxonrasib demonstrated unprecedented survival benefits in pancreatic cancer, driving strong investor support and a $2 billion capital raise. Multiple registrational trials are underway across pancreatic, lung, and colorectal cancers, with robust financial resources and global commercialization plans in place.
Revolution Medicines Earnings release: Q1 2026
Revolution Medicines released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.